100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes 100% increase in SCr at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ infection at 36 months · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ infection at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ malignancy at 36 months · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher complete remission at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment may leads to higher recurrence of disease (relapse) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to lower 100% increase in serum creatinine at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher adverse events: temporary/permanent discontinuation or… compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events: infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: infection at 3 years compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: malignancy at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Meters change from baseline in 6MWD · pulmonary arterial hypertension
1 finding from 1 review
Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension
1 finding from 1 review
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension
1 finding from 1 review
Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Change in height · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in longitudinal growth: change in height SDS compared with placebo or no intervention (low certainty).
1 finding from 1 review
Measures of mineral metabolism: change in serum phosphate mmol/L · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of mineral metabolism: change in serum phosphate mmol/L compared with placebo or no intervention (very low certainty).
1 finding from 1 review